Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
PT-141 (bremelanotide) is a non hormonal synthetic peptide that stimulates receptors in the brain to boost libido and sexual arousal & desire. Unlike traditional ED medications that target blood flow (PDE5: Sildenafil or Tadalafil), it addresses the brains desire. It is FDA-approved (as Vyleesi) and often used off-label for men. When activated, many people notice a gradual increase in sexual interest and desire.
Key Components and Benefits:
Mechanism: It acts on the hypothalamus—the part of the brain controlling sexual motivation. It essentially turns the "want" back on rather than just helping with mechanical function.
Indications: Formally approved for premenopausal women with hypoactive sexual desire disorder (HSDD). Men use it off-label when ‘non-blood flow’ barriers hinder physical arousal. The ‘on’ switch.
FDA approved—proven to increase your desire and reduce your distress
45 minutes prior to sexual activity and it reaches maximum concentration in the body within 30–60 minutes of administration.
PT-141 (bremelanotide) is a non hormonal synthetic peptide that stimulates receptors in the brain to boost libido and sexual arousal & desire. Unlike traditional ED medications that target blood flow (PDE5: Sildenafil or Tadalafil), it addresses the brains desire. It is FDA-approved (as Vyleesi) and often used off-label for men. When activated, many people notice a gradual increase in sexual interest and desire.
Key Components and Benefits:
Mechanism: It acts on the hypothalamus—the part of the brain controlling sexual motivation. It essentially turns the "want" back on rather than just helping with mechanical function.
Indications: Formally approved for premenopausal women with hypoactive sexual desire disorder (HSDD). Men use it off-label when ‘non-blood flow’ barriers hinder physical arousal. The ‘on’ switch.
FDA approved—proven to increase your desire and reduce your distress
45 minutes prior to sexual activity and it reaches maximum concentration in the body within 30–60 minutes of administration.